Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554231 | 0.92 | HTT (0.41) | HTTADRB2CYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL16563005 | 0.89 | HTT (0.44) | HTTADRB2CYP3A4SMN1; SMN2HTR1B | |
| SCHEMBL10175239 | 0.89 | HTR1B (0.40) | HTTCYP3A4SMN1; SMN2HTR1BSMYD2 | |
| SCHEMBL31682488 | 0.86 | KDM4E (0.41) | HTTCYP3A4SMN1; SMN2DRD2DRD4 | |
| SCHEMBL18286159 | 0.85 | ALDH1A1 (0.41) | HTTCYP3A4SMN1; SMN2SMYD2GAA | |
| SCHEMBL31704177 | 0.84 | ALDH1A1 (0.42) | HTTCYP3A4SMN1; SMN2HTR1B | |
| SCHEMBL29135908 | 0.84 | SIGMAR1 (0.45) | HTTDRD2DRD4DRD3 | |
| SCHEMBL553963 | 0.83 | HTR1B (0.46) | HTTCYP3A4SMN1; SMN2HTR1BSMYD2 | |
| SCHEMBL21878235 | 0.82 | CYP3A4 (0.40) | HTTCYP3A4SMN1; SMN2HTR1BSMYD2 | |
| SCHEMBL8720926 | 0.82 | LTA4H (0.40) | HTTCYP3A4SMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2024-06-06 | — | — | US | disclosed |
| CN-118084904-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084905-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111801327-B | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11590126-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | HTT 3091/4885ADRB2 2818/4885CYP3A4 563/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | HTT 3091/4885ADRB2 2818/4885CYP3A4 563/4885 |
| US-11590126-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | HTT 3091/4885ADRB2 2818/4885CYP3A4 563/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | HTT 3192/4885ADRB2 3417/4885CYP3A4 1309/4885 |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | HTT 3091/4885ADRB2 2818/4885CYP3A4 563/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | HTT 3192/4885ADRB2 3417/4885CYP3A4 1309/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | HTT 3761/4885ADRB2 4658/4885CYP3A4 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.